Bisphosphonates have been shown to reduce the risk of osteoporotic fractures. To avoid possible side effects of long-term therapy, many patients take a drug holiday after several years of bisphosphonate therapy. A team from ...
Jul 29, 2020
0
0
Uli von Andrian is the Mallinckrodt Professor of Immunopathology at Harvard Medical School and Program Leader of Basic Immunology at the Ragon Institute of MGH, MIT, and Harvard.
Apr 10, 2020
0
60
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following ...
Jul 8, 2019
0
1
USC researchers and collaborators report a breakthrough to prevent damage to the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis.
Apr 11, 2019
0
7
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news ...
Mar 25, 2019
0
1
Patients who take osteoporosis drugs for long periods typically are advised to temporarily discontinue the drugs to prevent rare but serious side effects to the jaw and thighs.
May 4, 2018
0
4
Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their ...
Nov 5, 2017
0
1
Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for ...
Oct 11, 2017
0
45
Osteoporosis is a disease that causes thinning of the bones, loss of bone density, and increasingly fragile bones. This puts people at higher risk for bone fractures. Risk for the disease increases as we age. In fact, 50% ...
Jun 2, 2017
0
4
(HealthDay)—The risk of osteonecrosis of the jaw (ONJ) is highest in association with intravenous bisphosphonate use, according to a study published online Aug. 19 in the Journal of Bone and Mineral Research.
Aug 31, 2015
0
5
